Medroxyprogesterone acetate (MPA) is a first generation progestin that has been in clinical
use for various hormonal conditions in women since the 1960s. Although developed as a …

In this issue of The Oncologist, Agarwal et al. report negative results from a phase I trial of
LFA102. Although “negative” in terms of antitumor activity, the study provides useful …

Purpose: Triple-negative breast cancer (TNBC) accounts for 10% to 20% of newly
diagnosed invasive breast cancer. Finding effective targets for chemotherapy-resistant …

Background: Progesterone receptor (PR) expression assessment in early invasive breast
cancer remains controversial. This study sought to re-evaluate PR expression as a potential …

Purpose: No study has yet analyzed whether changes in relative expression levels of
progesterone receptor (PR) isoforms A and B in human breast tumors have significance in …

Background Endocrine therapies targeting estrogen signaling have significantly improved
breast cancer (BC) patient survival, although 40% of ERα-positive BCs do not respond to …

The progesterone receptor (PgR), a member of the nuclear receptor family, is a well-known
oestrogen receptor (ER)-regulated gene that is expressed in over two-thirds of ER-positive …

The progesterone receptor (PR) is a key player in major physiological and pathological
responses in women, and the signaling pathways triggered following hormone binding have …

It is known that progesterone receptor (PR) isoform A (PR‐A) and isoform B (PR‐B) may
mediate different effects of progesterone. The objective of this study was to determine if the …

Accumulating evidence indicates that progestins are involved in controlling mammary gland
tumorigenesis. Here, we assessed the molecular mechanisms of progestin action in breast …